From the Prescribing Information that comes with each container of monthly Xtandi, one can find the highlights of Study 2, for Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer. 872 received Xtandi and 845 received a Placebo. In this Study, the Median Radiographic-free Survival of patients treated with Xtandi was 13.8 months. The median time to initiation of cytotoxic Chemotherapy was 28.0 months. The median time to first Skeletal-related Event (defined as radiation therapy or surgery to bone for prostate cancer, pathologic bone fracture, spinal cord compression, or change of antineoplastic therapy to treat bone pain) was 31.1 months. And, the median Overall Survival was 35.3 months.
Individual results may vary widely.
(I had a starting PSA of 5,006 with many bone and lymph node mets at age 65 in Nov 2013. Lupron ADT + Zometa resulted in a PSA nadir of 1.0. Castration-resistance took PSA back up to 95. Subsequent Xtandi for the past 9 months has taken my PSA back down to 1.5, so far.)
I concur with Beth about
checking insurance coverage & drug Formularies for Xtandi.
I'm on Medicare primary, with a nation-wide federal retiree version of Blue Cross Blue Shield as secondary.
Xtandi for me is a Tier 4 drug requiring Pre-Approval, and the use of a Specialty Pharmacy. My monthly copay is $35.
If your income has changed, and now meets assistance criteria, perhaps you could now get some $ assistance from the makers of Xtandi. See the link at their website.
Some other Financial Resources might be found here:
/www.pcf.org/c/financial-resources/Charles